Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine
Brief Summary
This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
Condition or Disease
- Pharmacokinetics
Phase
Study Design
| Study type: | INTERVENTIONAL |
|---|---|
| Status: | Unknown status |
| Study results: | No Results Available |
| Age: | 18 Years and older (Adult, Older Adult) |
| Enrollment: | 48 (ESTIMATED) |
| Funded by: | Industry |
| Allocation: | Randomized |
| Primary Purpose: | Treatment |
Masking |
|
Clinical Trial Dates
| Start date: | Aug 01, 2007 | |
|---|---|---|
| Primary Completion: | Feb 01, 2008 | ACTUAL |
| Completion Date: | Mar 01, 2008 | ESTIMATED |
| Study First Posted: | Aug 23, 2007 | ESTIMATED |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Feb 27, 2008 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
To assess separately the effects of a nasal vasoconstrictor (oxymetazoline) and of a nasal steroid on the rate and extent of intranasal absorption of PMI-150 30 mg.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Healthy Volunteers: | Yes |
Inclusion Criteria:
* Healthy adults
* Patients with Allergic Rhinitis
Exclusion Criteria:
* Under age 18
* Healthy adults
* Patients with Allergic Rhinitis
Exclusion Criteria:
* Under age 18
Primary Outcomes
-
Pharmacokinetics multiple
More Details
| NCT Number: | NCT00520104 |
|---|---|
| Other IDs: | KET-PK-008 |
| Study URL: | https://clinicaltrials.gov/study/NCT00520104 |
Last updated: Sep 29, 2023